[Role of phosphatidylinositol 3-kinase in platelet aggregation in type 1 diabetes mellitus].
It was found that incubation of platelet rich plasma with wortmannin, an irreversible selective inhibitor of phosphoinositide 3-kinase (PI3K), leads to sharp drop in platelet aggregation ability in healthy donors, whereas in type 1 diabetes mellitus patients this effect was less manifested or not quite determined. Translocation dynamics of PI3K regulatory subunit into cytoskeleton fraction under induction of platelet aggregation by various ADP concentrations and after wortmannin treatment was studied. Reciprocal interaction of endothelial constitutive NO synthase with PI3K in mechanisms of platelet functional state regulation under studied pathological and normal conditions have been analyzed.
Sybirna
N O
NO
Vovk
O I
OI
Velykyĭ
M M
MM
D000328:Adult; D000730:Androstadienes / Q000494:pharmacology; D001792:Blood Platelets / Q000187:drug effects* / Q000201:enzymology; D003922:Diabetes Mellitus, Type 1 / Q000097:blood* / Q000201:enzymology; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D019869:Phosphatidylinositol 3-Kinases / Q000097:blood / Q000378:metabolism*; D000081082:Phosphoinositide-3 Kinase Inhibitors; D010974:Platelet Aggregation / Q000187:drug effects*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D000077191:Wortmannin
D000730:Androstadienes; D019869:Phosphatidylinositol 3-Kinases; D000081082:Phosphoinositide-3 Kinase Inhibitors; D047428:Protein Kinase Inhibitors; D000077191:Wortmannin